← Back to patent-cliff list
SM-020
Tier C — Watch / tradeSM-020
SeylanMED LLC
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：C-akt
Indications (approved)：皮肤肿瘤, 皮肤性疾病, 脂溢性角化病, Basal cell carcinoma
Regional status
US
Phase II
2023-11-07
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SM-020?
Approved indications include: 皮肤肿瘤, 皮肤性疾病, 脂溢性角化病, Basal cell carcinoma.
When does the SM-020 patent expire?
No public expiry year is available for SM-020 yet; this page updates once verified.
How do I get a quote for SM-020 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21